Glucosamine Linked to 25% Higher Dementia Progression Risk — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- UF researchers analyzed health records from 2012–2024 and found glucosamine use associated with a 25% higher likelihood that mild cognitive impairment would progress to dementia, after adjusting for demographics
- Glucosamine users already diagnosed with Alzheimer's or related dementias showed a 25% higher mortality risk compared to non-users in the same diagnostic group, though no mortality link appeared in the MCI group
- Study data covered 1,896 ADRD patients and 2,750 MCI patients, with 8% in each group reporting glucosamine use, per the AI-assisted analysis of deidentified UF Health records
- Mouse experiments showed glucosamine increased sugar-tag attachment to proteins inside cells and worsened social memory deficits, while suppressing the tagging process restored memory performance
- Human Alzheimer's brain tissue from the UF Neuromedicine Brain and Tissue Bank showed significantly more protein sugar-tagging than tissue from healthy controls
- Ramon Sun, Ph.D., senior author and director of UF's Center for Advanced Spatial Biomolecule Research, said altered metabolism could become a target complementing existing plaque-and-tangle Alzheimer's approaches
- Co-author Matt Gentry, Ph.D. called the electronic health-record data "very provocative" but stressed it remains an association, not proof of causality, and urged a controlled human clinical trial
Why it matters: With roughly 7 million Americans living with Alzheimer's and glucosamine widely available over the counter and especially popular among older adults, a 25% higher MCI-to-dementia progression risk is a high-stakes public health question. Researchers stopped short of telling patients to stop the supplement and called for a controlled human clinical trial before any clinical guidance changes.
Ask SkimNews
